Welcome to our dedicated page for Arcadia Biosciences SEC filings (Ticker: RKDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Arcadia Biosciences, Inc. filings document the company's plant-based products business, operating results, governance matters, and capital structure. Its 8-K reports cover material agreements, inducement transactions involving preferred investment options and common stock, shareholder voting matters, board changes, and changes in the company's independent registered public accounting firm.
Arcadia's proxy and periodic disclosures address executive compensation, board governance, internal control over financial reporting, going-concern risk language, and other risks associated with recurring losses, cash use, financing needs, and public-company compliance.
Arcadia Biosciences, Inc. (RKDA) reported the results of its September 10, 2026 annual meeting, where holders of 1,259,315 shares of common stock, representing 52.3% of shares outstanding on the record date, were present in person or by proxy. Stockholders elected Gregory D. Waller as a Class II director, approved the potential issuance of common stock upon exercise of the Series A-1 Preferred Investment Options issued in the June 12, 2026 private placement, and approved the new 2026 Omnibus Equity Incentive Plan, which replaces the expired 2015 plan.
Stockholders also approved an amendment authorizing the Board, in its discretion, to implement a reverse stock split at a ratio between 1-for-2 and 1-for-10 any time before June 30, 2027. In addition, they approved, on an advisory basis, executive compensation, ratified Ramirez Jimenez International CPAs as independent registered public accountants for 2026, and approved a proposal allowing adjournment of the meeting if additional time for votes on Proposals 2 or 4 is required.
Arcadia Biosciences, Inc. (RKDA) reported that director Amy Yoder received a grant of stock options covering 10,000 shares of common stock on September 10, 2026. The options have an exercise price of $0.46 per share and expire on September 10, 2036. They vest 100% on the earlier of September 10, 2027 or the next Annual Meeting of Stockholders, subject to her continued service, after which her directly held derivative position reported in this grant totals 23,442 options.
Arcadia Biosciences, Inc. (RKDA) reported that director Kevin Comcowich received a grant of 23,000 stock options on September 10, 2026, with an exercise price of $0.46 per share and an expiration date of September 10, 2036. These options vest 100% on the earlier of September 10, 2027 or the company’s next Annual Meeting of Stockholders, subject to his continued service, bringing his reported outstanding option holdings to 54,042 options. No Rule 10b5-1 trading plan is reported for this award.
Arcadia Biosciences, Inc. (RKDA) reported that director Gregory D. Waller received a grant of stock options for 10,000 shares of common stock on September 10, 2026. The options have an exercise price of $0.46 per share, expire on September 10, 2036, and leave him with 23,338 options held directly after the grant. The award will become 100% vested and exercisable on the earlier of September 10, 2027 or the date of the company’s next Annual Meeting of Stockholders, subject to his continued service, and no Rule 10b5-1 trading plan is reported.
Arcadia Biosciences, Inc. (RKDA) reported that director Murray Lilian Shackelford received a grant of 10,000 stock options on September 10, 2026. The options have an exercise price of $0.46 per share and expire on September 10, 2036. They become 100% vested and exercisable on the earlier of September 10, 2027 or the date of Arcadia’s next Annual Meeting of Stockholders, subject to continued service. Following this grant, Shackelford holds 23,287 derivative securities directly.
Arcadia Biosciences, Inc. (RKDA) reports that on August 31, 2026 it received a notice from Nasdaq’s Listing Qualifications Department that its stockholders’ equity no longer meets the Nasdaq Capital Market’s continued listing standard requiring at least $2,500,000 of stockholders’ equity.
Arcadia reported stockholders’ equity of $633,000 as of June 30, 2026 and also does not meet Nasdaq’s alternative market value or net income criteria, so it is currently out of compliance. The common stock continues to trade on the Nasdaq Capital Market while the company has 45 days, until October 15, 2026, to submit a plan to regain compliance. If Nasdaq accepts the plan, Arcadia may receive up to 180 days from the notice date to demonstrate compliance, but there is no assurance the plan will be accepted or that compliance will be achieved, and an appeal process is available if a plan is rejected.
Armistice Capital, LLC and Steven Boyd report beneficial ownership of Arcadia Biosciences, Inc. common stock. They report beneficial ownership of 267,392 shares, representing 9.99% of the outstanding common stock. All 267,392 shares are subject to shared voting and shared dispositive power, with no sole voting or dispositive power reported. The shares are held by Armistice Capital Master Fund Ltd., for which Armistice Capital acts as investment manager pursuant to an Investment Management Agreement. Steven Boyd, as managing member of Armistice Capital, may also be deemed to beneficially own these securities.
Arcadia Biosciences, Inc. reported Q2 2026 product revenues of $1.4 million, essentially flat versus Q2 2025, all from Zola coconut water. For the first six months of 2026, revenues were $2.5 million, down modestly from the prior-year period.
The company generated a Q2 2026 net loss attributable to common stockholders of $6.3 million and a year‑to‑date loss of $10.7 million, driven by a $5.4 million valuation loss on the June 2026 PIPE financing, a $2.9 million loss on the January 2026 inducement offer, unrealized losses on AFII shares, and issuance and offering costs. Selling, general and administrative expenses declined sharply year over year, reflecting lower M&A and employee costs.
At June 30, 2026, cash and cash equivalents were $4.2 million, total assets $5.9 million, and stockholders’ equity $0.6 million, with $3.6 million of warrant and option liabilities. Management states that existing cash will not meet anticipated needs for at least 12 months, raising substantial doubt about the ability to continue as a going concern absent additional financing or asset sales.
Arcadia Biosciences, Inc. reported second-quarter and first-half 2026 results, showing relatively stable revenues but significantly higher net losses driven largely by financing-related and fair value items. Total revenues were $1.4 million for the quarter and $2.5 million for the first half, down modestly year over year, primarily due to low inventory and shipping delays affecting Zola sales. Second-quarter loss from continuing operations was $0.5 million, but net loss attributable to common stockholders widened to $6.3 million, and to $10.7 million for the first half, reflecting unrealized losses on Above Food stock, a $5.4 million valuation loss on the June 2026 PIPE, a $2.9 million loss on the January 2026 inducement offer, and offering costs, partly offset by gains on warrant and option liabilities.
Operating trends were more favorable: cash used in operating activities was only $319,000 in the quarter, SG&A expenses declined by $1.0 million in the quarter and $1.6 million in the first half versus 2025, and cash and cash equivalents rose to $4.2 million at June 30, 2026, supported by a $4.0 million PIPE and additional financing. Management highlighted strong recent Zola sales momentum and multiple product launches planned through 2027, while also disclosing that additional funding will be required to continue operations and planned activities and that any further equity financing could dilute existing stockholders.